Results 21 to 30 of about 15,613 (254)
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]
, 2018 Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo +4 more
core +1 more source
Paroxysmal Nocturnal Hemoglobinuria: New Thoughts [PDF]
, 1970 I have tried to summarize some of the facts we know, and some questions we need to ask in a disease which, although it is not common, probably is not as rare as we once thought.
Rosse, Wendell F.
core +9 more sources
Frequency of paroxysmal nocturnal hemoglobinuria in patients attended in Belém, Pará, Brazil
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: Paroxysmal nocturnal hemoglobinuria is a hematological disease with complex physiopathology. It is genetically characterized by a somatic mutation in the PIG-A gene (phosphatidylinositol glycan anchor biosynthesis, class A), in which the best
Lacy Cardoso de Brito Junior +5 more
doaj +1 more source
Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria [PDF]
, 2015 The clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hematologic disease, has fundamentally improved with the introduction of a therapeutic that prevents complement-mediated intravascular hemolysis. However, a
Koutsogiannaki, Sophia +6 more
core +1 more source
Paroxysmal Nocturnal Hemoglobinuria
JAMA, 1973 A 66-year-old white man with a previously normal hematological history was studied for hemolysis during the recovery phase of acute tubular necrosis. He demonstrated a persistently worsening anemia in the absence of blood loss and had an increase of his serum-free hemoglobin. A hemolytic process consistent with paroxysmal nocturnal hemoglobinuria (PNH)
E, Polli +4 more
+5 more sources
Haematologica, 2011 Background A deficiency of specific glycosylphosphatidyl inositol-anchored proteins in paroxysmal nocturnal hemoglobinuria may be responsible for most of the clinical features of this disease, but some functional consequences may be indirect. For example,
Anna M. Jankowska +7 more
doaj +1 more source
Paroxysmal nocturnal hemoglobinuria clone in 103 Brazilian patients: diagnosis and classification
Revista Brasileira de Hematologia e Hemoterapia, 2015 Background: Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic ane- mia, which often manifests as peripheral blood cytopenias and thrombosis. Objective: The aim of this study is to describe a Brazilian population of paroxysmal nocturnal
Ana Paula de Azambuja +5 more
doaj +1 more source
Positive predictive value of diagnosis coding for hemolytic anemias in the Danish National Patient Register [PDF]
, 2016 PURPOSE: The nationwide public health registers in Denmark provide a unique opportunity for evaluation of disease-associated morbidity if the positive predictive values (PPVs) of the primary diagnosis are known.
Frederiksen, Henrik +3 more
core +2 more sources
Haematologica, 2017 Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement ...
Xuan Yuan +8 more
doaj +1 more source
Haematologica, 2010 Background Clones of glycosylphosphatidylinositol-anchor protein-deficient cells are characteristic in paroxysmal nocturnal hemoglobinuria and are present in about 40–50% of patients with severe aplastic anemia.
Phillip Scheinberg +3 more
doaj +1 more source